CD30 Ligand, a Member of the TNF Ligand Superfamily, with Growth and Activation Control for CD30+ Lymphoid and Lymphoma Cells*

Leukemia and Lymphoma

Volumn 20, Issue 42130, 1996, Pages 397-409

  Gruss, Hans Jürgen ^a   Herrmann, Friedhelm ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

CD30; CD30 ligand; growth control; lymphomas; TNF ligands; TNF receptors

Indexed keywords

CD30 ANTIGEN; CELL SURFACE RECEPTOR; CYTOKINE RECEPTOR; NERVE GROWTH FACTOR RECEPTOR; RECOMBINANT PROTEIN; TUMOR MARKER; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN EXPRESSION; B LYMPHOCYTE; BURKITT LYMPHOMA; GENE LOCATION; GROWTH REGULATION; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LARGE CELL LYMPHOMA; LYMPHOCYTE PROLIFERATION; LYMPHOID CELL; LYMPHOMA CELL; MOLECULAR CLONING; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN FAMILY; RECEPTOR BINDING; RECEPTOR GENE; REED STERNBERG CELL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD30; CD30 LIGAND; CELL DIFFERENTIATION; CELL DIVISION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 9; CLONING, MOLECULAR; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HODGKIN DISEASE; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; LYMPHOMA; MEMBRANE GLYCOPROTEINS; MULTIGENE FAMILY; NEOPLASM PROTEINS; NEOPLASMS; RECEPTORS, CYTOKINE; RECOMBINANT FUSION PROTEINS; REED-STERNBERG CELLS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0029867276     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428199609052421     Document Type: Article

References (79)

1. Kaplan H. S. Hodgkin's Disease. Harvard University Press, Boston, MA 1980
2. Poppema S., Kaleta J., Hepperle B. Chromosomal abnormalities in patients with Hodgkin's disease: evidence for frequent involvement of the 14q chromosomal region but infrequent bcl-2 gene rearrangement in Reed-Sternberg cells. J. Natl. Cancer Inst. 1992; 84: 1789 – 1793
3. Trümper L. M., Brady G., Bagg A., Gray D., Loke S. L., Griesser H., Wagman R., Braziel R., Gascoyne R. D., Vicini S., Iscove N. N., Cossman J., Mak T. W. Single-cell analysis of Hodgkin and Reed-Stemberg cells: molecular heterogeneity of gene expression and p53 mutations. Blood 1993; 81: 3097 – 3115
4. Küppers R., Rajewsky K., Zhao M., Simons G., Laumann R., Fischer R., Hansmann M.-L. Hodgkin disease: Hodgkin and Reed-Stemberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc. Natl. Acad. Sci. USA 1994; 91: 10962 – 10966
5. Drexler H. G. Recent results on the biology of Hodgkin and Reed-Stemberg cells, I. Biopsy material. Leuk. Lymphoma 1992; 8: 283 – 313
6. Haluska F. G., Brufsky A. M., Canellos G. P. The cellular biology of the Reed-Stemberg cell. Blood 1994; 84: 1005 – 1019
7. Kaufman D., Longo D. L. Hodgkin's disease. Crit. Rev. Oncol. Hematol. 1992; 13: 135 – 156
8. Gruss H.-J., Herrmann F., Drexler H. G. Hodgkin's disease: a cytokine producing tumor. Crit. Rev. Oncogenesis 1994; 5: 473 – 538
9. Hsu S. M., Waldron J. W., Hsu P. L., Hough A. J. J. Cytokines in malignant lymphomas: review and prospective evaluation. Hum. Pathol. 1993; 24: 1040 – 1057
10. Kadin M. E. Pathology of Hodgkin's disease. Curr. Opini. Oncol. 1994; 6: 456 – 463
11. Drexler H. G. Recent results on the biology of Hodgkin and Reed-Stemberg cells. II. Continuous cell lines. Leuk. Lymphoma 1993; 9: 1 – 25
12. Herbst H., Stein H., Niedobitek G. Epstein-Barr virus and CD30+ malignant lymphomas. Crit. Rev. Oncog. 1993; 4: 191 – 239
13. Schwab U., Stein H., Gerdes J., Lemke H., Kirchner H., Schaadt M., Diehl V. Production of a monoclonal antibody specific for Hodgkin and Stemberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982; 299: 65 – 67
14. Hecht T. T., Longo D. L., Cossman J., Bolen J. B., Hsu S. M., Israel M., Fisher R. I. Production and characterization of a monoclonal antibody that binds Reed-Stemberg cells. J. Immunol. 1985; 134: 42314236
15. Schwarting R., Gerdes J., Dürkop H., Falini B., Pileri S., Stein H. BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 1989; 74: 1678 – 1689
16. Pfreundschuh M., Mommertz E., Meissner M., Feller A. C., Hassa R., Krueger G. R., Diehl V. Hodgkin and Reed-Sternberg cell associated monoclonal antibodies HRS-1 and HRS-2 react with activated cells of lymphoid and monocytoid origin. Anticancer Res. 1988; 8: 217 – 224
17. Bowen M. A., Olsen K. J., Cheng L., Avila D., Podack E. R. Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R. and induction of homotypic aggregation. J. Immunol. 1993; 151: 5896 – 5906
18. Smith C. A., Gruss H.-J., Davis T., Anderson D., Farrah T., Baker E., Sutherland G. R., Brannan C. I., Copeland N. G., Jenkins N. A., Grabstein K. H., Gliniak B., McAlister I. B., Fanslow W., Alderson M., Falk B., Gimpel S., Gillis S., Din W. S., Goodwin R. G., Armitage R. J. CD30 antigen. a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993; 73: 1349 – 1360
19. Gruss H. J., Boiani N., Williams D. E., Armitage R. J., Smith C. A., Goodwin R. G. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994; 83: 2045 – 2056
20. Falini B., Pileri S., Pizzolo G., Dürkop H., Flenghi L., Stirpe F., Martelli M. F., Stein H. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995; 85: 1 – 14
21. Dürkop H., Latza U., Hummel M., Eitelbach F., Seed B., Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992; 68: 421 – 427
22. Farrah T., Smith C. A. Emerging cytokine family. Nature 1992; 358: 26
23. Gruss H.-I., Ulrich D., Braddy S., Armitage R. J., Dower S. K. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Stemberg cells. Eur. J. Immunol. 1995, in press
24. Gruss H.-J., Hirschstein D., Alderson M. R., Armitage R. J. Regulation of CD30 ligand expression on peripheral blood T cells: functional involvement in T-T cell interaction. J. Immunol. 1995, in press
25. DelPrete G. F., De Carli M., Almerigogna F., Daniel C. K., D'Elios M. M., Zancuoghi G., Pizzolo G., Romagnani S. Preferential expression of CD30 by human CD4i T cells producing Th2-type cytokines. FASEB J. 1995; 9: 81 – 86
26. Manetti R., Annunziato F., Biagiotti R., Giudizi M. G., Piccinni M.-P., Giannarini L., Sampognaro S., Panonchi P., Vinante F., Pizzolo G., Maggi E., Romagnani S. CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+ T cell clones in human immunodeficiency virus infection. J. Exp. Med. 1994; 180: 2407 – 2411
27. DelPrete G., Maggi E., Pizzolo G., Romagnani S. CD30, Th2 cytokines and HIV infection: a complex and fascinating link. Immunol. Today 1995; 16: 76 – 80
28. Stein H., Gerdes J., Schwab U., Lemke H., Mason D., Ziegler A., Schienle W., Diehl V. Identification of Hodgkin and Stemberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int. J. Cancer 1982; 30: 445 – 449
29. Stein H., Mason D. Y., Gerdes J., O'Connor N., Wainscoat J., Pallesen G., Gatter K., Falini B., Delsol G., Lemke H., Schwarting R., Lennert K. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848 – 858
30. Froese P., Lemke H., Gerdes J., Havsteen B., Schwarting R., Hansen H., Stein H. Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines. J. Immunol. 1987; 189: 2081 – 2087
31. Nawrocki I. F., Kirsten E. S., Fisher R. I. Biochemical and structural properties of a Hodgkin's disease-related membrane protein. J. Immunol. 1988; 141: 672 – 680
32. Drexler H. G., Jones D. B., Diehl V., Minowada J. Is the Hodgkin cell a T- or B-lymphocyte? Recent evidence from geno-and immunophenotypic analysis and in-vitro cell lines. Hematol. Oncol. 1989; 7: 95 – 113
33. Pfreundschuh M., Pohl C., Berenbeck C., Schroeder J., Jung W., Schmits R., Tschiersch A., Diehl V., Gause A. Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma. adult T-cell leukemia and infectious mononucleosis. Int. J. Cancer 1990; 45: 869 – 874
34. Pizzolo G., Vinante F., Chilosi M., Dallenbach F., Josimovic-Alasevic O., Diamantstein T., Stein H. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage. Br. J. Haematol. 1990; 75: 282 – 284
35. Gause A., Pohl C., Tschiersch A., Da Costa L., Jung W., Diehl V., Hasenclever D., Pfreundschuh M. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood 1991; 77: 1983 – 1988
36. Nadali G., Vinante F., Ambrosetti A., Todeschini G., Veneri D., Zanotti R., Meneghini V., Ricetti M. M., Benedetti F., Vassanelli A., Perona G., Chilosi M., Menestrina F., Fiacchini M., Stein H., Pizzolo G. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J. Clin. Oncol. 1994; 12: 793 – 797
37. Josimovic-Alasevic O., Dürkop H., Schwarting R., Backe E., Stein H., Diamantstein T. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur. J. Immunol. 1989; 19: 157 – 162
38. Smith C. A., Farrah T., Goodwin R. G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994; 75: 959 – 962
39. Armitage R. J. Tumor necrosis factor receptor superfamily members and their ligands. Curr. Opin. Immunol. 1994; 6: 407 – 413
40. Banchereau J., Bazan F., Blanchard D., Briere F., Galizzi J.-P., Van Kooten C., Liu Y. J., Rousset F., Saeland S. The CD40 antigen and its ligand. Annu. Rev. Immunol. 1994; 12: 881 – 922
41. Crowe P. D., VanArsdale T. L., Walter B. N., Ware C. F., Hession C., Ehrenfels B., Browning J. L., Din W. S., Goodwin R. G., Smith C. A. A lymphotoxin—specific receptor. Science 1994; 264: 707 – 710
42. Jones E. Y., Stuart D. I., Walker N. P. The three-dimensional structure of tumour necrosis factor. Prog. Clin. Biol. Res. 1990; 349: 321 – 327
43. Eck M. J., Ultsch M., Rinderknecht E., De Vos A. M., Sprang S. R. The structure of human lymphotoxin (tumor necrosis factor-β) at 1.9-Å resolution. J. Bid. Chem. 1992; 267: 2119 – 2122
44. Banner D. W., D'Arcy A., Janes W., Gentz R., Schoenfeld H.-J., Broger C., Loetscher H., Lesslauer W. Crystal structure of the soluble human 55 kd TNF receptor-human TNFB complex: implications for TNF receptor activation. Cell 1993; 73: 431 – 445
45. Peitsch M. C., Jongeneel C. V. A 3-D model for the CD40 ligand predicts that it is a compact trimer similar to the tumor necrosis factors. Int. Immunol. 1993; 5: 233 – 238
46. Fonatsch C., Latza U., Dürkop H., Rieder H., Stein H. Assignment of the human CD30 (Ki-1) gene to 1p36. Genomics 1992; 14: 825 – 826
47. Gruss H.-J., Dower S. K. TNF ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995; 85: 3378 – 3404
48. Ellis T. M., Simms P. E., Slivnick D. J., Jäck H.-M., Fisher R. I. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J. Immunol. 1993; 151: 2380 – 2389
49. Andreesen R., Osterholz J., Lohr G. W., Bross K. J. A Hodgkin cell-specific antigen is expressed on a subset of auto- and alloactivated T (helper) lymphoblasts. Blood 1984; 63: 1299 – 1302
50. Andreesen R., Brugger W., Lohr G. W., Bross K. J. Human macrophages can express the Hodgkin's cell-associated antigen Ki-1 (CD30). Am. J. Pathol. 1989; 134: 187 – 192
51. Gruss H.-J., Da Silva N., Hu Z.-B., Uphoff C. C., Goodwin R. G., Drexler H. G. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines. Leukemia 1994; 8: 2083 – 2094
52. Cambiaggi A., Cantoni C., Marciano S., De Totero D., Pileri S., Tazzari P. L., Stein H., Ferrini S. Cultured human NK cells express the Ki-1/CD30 antigen. Br. J. Haematol. 1993; 85: 270 – 276
53. Pallesen G., Hamilton-Dutoit S. I. Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma. Am. J. Pathol. 1988; 133: 446 – 450
54. Mechtersheimer G., Moller P. Expression of Ki-1 antigen (CD30) in mesenchymal tumors. Cancer 1990; 66: 1732 – 1737
55. Beutler B. Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine. Raven Press, New York 1992
56. Delabie J., Ceuppens J. L., Vandenberghe P., De Boer M., Coorevits L., De Wolf-Peeters C. The B7/BB1 antigen is expressed by Reed-Stemberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. Blood 1993; 82: 2845 – 2852
57. Munro J. M., Freedman A. S., Aster J. C., Gribben J. G., Lee N. C., Rhynhart K. K., Banchereau J., Nadler L. M. In vivo expression of the 87 costimulatory molecule by subsets of antigen-presenting cells and malignant cells of Hodgkin's disease. Blood 1994; 83: 793 – 798
58. Ruco L. P., Pomponi D., Pigott R., Gearing A. J., Baiocchini A., Baroni C. D. Expression and cell distribution of the intercellular adhesion molecule, vascular cell adhesion molecule, endothelial leukocyte adhesion molecule, and endothelial cell adhesion molecule (CD31) in reactive human lymph nodes and in Hodgkin's disease. Am. J. Pathol. 1992; 140: 1337 – 1344
59. Gruss H.-J., Hirschstein D., Wright B., Ulrich D., Caligiuri M. A., Barcos M., Strockbine L., Armitage R. J., Dower S. K. Expression and function of CD40 on Hodgkin and Reed-Stemberg cells and the possible relevance for Hodgkin's disease. Blood 1994; 84: 2305 – 2314
60. Yonehara S., Ishii A., Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 1989; 169: 1747 – 1756
61. Trauth B. C., Klas C., Peters A. M. J., Matzku S., Moller P., Falk W., Debatin K.-M., Krammer P. H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301 – 305
62. Mason D. Y., Bastard C., Rimokh R., Dastugue N., Huret J. L., Kristoffersson U., Magaud J.-P., Nezelof C., Tilly H., Vannier J. P., Hemet J., Warnke R. CD30-positive large cell lymphomas (‘Ki-1 lymphoma’) are associated with a chromosomal translocation involving 5q35. Br. J. Haematol. 1990; 74: 161 – 168
63. LeBeau M. M., Bitter M. A., Larson R. A., Doane L. A., Ellis E. D., Franklin W. A., Rubin C. M., Kadin M. E., Vardiman J. W. The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. Leukemia 1989; 3: 866 – 870
64. Morris S. W., Kirstein M. N., Valentine M. B., Dittmer K. G., Shapiro D. N., Saltman D. L., Look A. T. Fusion of a ki-nase gene, ALK, to a nucleolar protein gene, NPM. in non-Hodgkin's lymphoma. Science 1994; 263: 1281 – 1284
65. Shiota M., Fujimoto J., Semba T., Satoh H., Yamamoto T., Mori S. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 1994; 9: 1567 – 1574
66. Falini B., Bolognesi A., Flenghi L., Tazzari P. L., Broe M. K., Stein H., Dürkop H., Aversa F., Corneli P., Pizzolo G., Barbabietola G., Sabattini E., Pileri S., Martelli M. F., Stirpe F. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 1992; 339: 1195 – 1196
67. Engert A., Burrows F., Jung W., Tazzari P. L., Stein H., Pfreundschuh M., Diehl V., Thorpe P. Evaluation of ricin A chain-containing immunotoxins directed against the CD3O antigen as potential reagents for the treatment of Hodgkin's disease. Cancer Res. 1990; 50: 84 – 88
68. Ito K., Watanabe T., Horie R., Shiota M., Kawamura S., Mori S. High expression of the CD30 molecule in human decid-ual cells. Am. J. Ptrrhol. 1994; 145: 276 – 280
69. Romagnani S. Lymphokine production by human T cells in disease states. Annu. Rev. Immtmol. 1994; 12: 227 – 257
70. Pizzolo G., Vinante F., Morosato L., Nadali G., Chilosi M., Gandini G., Sinicco A., Raiteri S., Semenzato G., Stein H., Perona G. High serum level of soluble form of CD30 molecule in the early phase of HIV-l infection as an independent predictor of progression co AIDS. AIDS 1994; 8: 741 – 745
71. Mills J. A. Systemic lupus erythematosus. New Engl, J. Med. 1994; 330: 1871 – 1879
72. Schall T. J., Lewis M., Koller K. J., Lee A., Rice G. C., Wong G. H. W., Gatanaga T., Granger G. A., Lentz R., Raab H., Kohr W. I., Goeddel D. V. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 1990; 61: 361 – 370
73. Smith C. A., Davis T., Anderson D., Solam L., Beckmann M. P., Jerzy R., Dower S. K., Cosman D., Goodwin R. G. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990; 248: 1019 – 1023
74. Loetscher H., Pan Y.-C. E., Lahm H.-W., Gentz R., Brockhaus M., Tabuchi H., Lesslauer W. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 1990; 61: 351 – 359
75. Alderson M. R., Armitage R. J., Maraskovsky E., Tough T. W., Roux E., Schooley K., Ramsdell F., Lynch D. H. Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med. 1993; 178: 2231 – 2235
76. Alderson M. R., Smith C. A., Tough T. W., Davis-Smith T., Armitage R. J., Falk B., Roux E., Baker E., Sutherland G. R., Din W. S., Goodwin R. G. Molecular and biological characterization of human 4-IBB and its ligand. Eur. J. fmmunol. 1994; 24: 2219 – 2227
77. Gause A., Scholz R., Klein S., Jung W., Diehl V., Tesch H., Hasenclever D., Pfreundschuh M. Increased levels of circulating interleukin-6 in patients with Hodgkin's disease. Hemurol. Oncol. 1991; 9: 307 – 313
78. Kurzrock R., Redman J., Cabanillas F., Jones D., Rothberg J., Talpaz M. Serum interleukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res. 1993; 53: 2118 – 2122
79. Gruss H.-J., Dölken G., Brach M. A., Mertelsmann R., Hemnann F. The significance of serum levels of soluble 60kDa receptors for tumor necrosis factor in patients with Hodgkin's disease. Leukemia 1993; 7: 1339 – 1343